News Datroway is first TROP2 drug for frontline breast cancer AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.
News Pfizer, Arvinas join SERD club with Veppanu approval Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
News FDA's ODAC delivers one loss, one win for AstraZeneca The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
News DNA testing can help right racial imbalance in breast cancer Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and Black women.
News Novartis snaps up PI3Kα breast cancer drug in $3bn deal Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
News Denying prostate cancer screening 'no longer rational' A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.